Company intelligence / Profile preview
Antios Therapeutics
Atlanta, Georgia, United Statesantiostherapeutics.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Antios Therapeutics was developing ATI‑2173, an oral liver-targeted prodrug designed to inhibit HBV DNA replication. The company advanced this candidate into Phase II clinical trials and explored combination regimens with other antivirals. However, development was halted after a clinical hold by the FDA due to safety concerns in mid‑2022. Operations ceased in early 2023.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (notably nucleotide analogs/prodrugs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Arbutus Biopharma Corporation – combination trial with AB‑729 RNAi therapeutic for HBVAssembly Biosciences – terminated collaboration following FDA clinical hold
Beyond the preview
Go deeper on Antios Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antios Therapeutics.